Q2 EPS Estimate for Bausch Health Cos Reduced by Analyst

Key Points

• Zacks Research has decreased its earnings per share (EPS) forecast for Bausch Health for Q2 2026 from $0.98 to $0.91, while the full-year earnings estimate is set at $4.41.
• Bausch Health's recent stock performance shows a trading price of $7.48, with a 52-week range between $4.25 and $9.85, reflecting market volatility.
• Insider transactions indicate confidence in the company, with director John Paulson acquiring over 34 million shares at approximately $9.00 per share, raising his stake significantly.

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Zacks Research lowered their Q2 2026 earnings per share estimates for shares of Bausch Health Cos in a research report issued on Wednesday, August 20th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.91 for the quarter, down from their previous estimate of $0.98. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos' FY2026 earnings at $4.07 EPS.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The firm had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS.

A number of other equities analysts also recently issued reports on BHC. Royal Bank Of Canada lifted their price target on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $9.00.

Bausch Health Cos Stock Up 3.6%

Bausch Health Cos stock traded up $0.26 during midday trading on Monday, reaching $7.41. The stock had a trading volume of 2,189,126 shares, compared to its average volume of 4,518,157. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $9.85. The company has a market capitalization of $2.74 billion, a P/E ratio of 28.50 and a beta of 0.41. The company has a fifty day moving average price of $6.73 and a two-hundred day moving average price of $6.06. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BHC. JPMorgan Chase & Co. grew its stake in shares of Bausch Health Cos by 1,246.0% during the fourth quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company's stock valued at $160,000 after buying an additional 18,366 shares during the last quarter. Two Sigma Investments LP lifted its holdings in Bausch Health Cos by 688.2% in the fourth quarter. Two Sigma Investments LP now owns 265,461 shares of the company's stock worth $2,140,000 after buying an additional 231,781 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Bausch Health Cos in the fourth quarter worth about $468,000. Raymond James Financial Inc. purchased a new stake in Bausch Health Cos in the fourth quarter worth about $180,000. Finally, Maple Rock Capital Partners Inc. increased its stake in shares of Bausch Health Cos by 156.7% during the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after purchasing an additional 3,235,100 shares in the last quarter. Institutional investors own 78.65% of the company's stock.

Insider Buying and Selling

In other news, Director John Paulson bought 34,721,118 shares of Bausch Health Cos stock in a transaction that occurred on Thursday, August 14th. The shares were acquired at an average price of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the purchase, the director directly owned 70,755,869 shares in the company, valued at $636,802,821. The trade was a 96.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders acquired a total of 44,316,834 shares of company stock valued at $369,628,560 over the last quarter. 8.05% of the stock is owned by corporate insiders.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.